Fig. 4
ZIKV neutralisation assay and antibody-dependent enhancement (ADE) to DENV2 infection. a Microneutralisation titre 50 (MN50) assay in Vero cells was assessed upon incubation of ZIKV-BR in the presence of serially diluted sera from BALB/c mice vaccinated with ChAdOx1 ZIKV vaccines at 4 weeks and 4 months. Results show the average of three biological replicates, with duplicates and black lines represents the mean (n = 6). A two-way ANOVA followed by Sidak’s Multiple comparison was performed. ****p < 0.0001, ***p < 0.0003. Supplementary Table 1 shows the multiple comparison between all the groups. b ELISA cross-reactivity of DENV1-4 in sera from mice vaccinated with the highly protective ChAdOx1 prME ∆TM vaccine. Bars represent the average and error is the s.d. c Infection of U937 cells by a DENV2 strain in the presence of sera from mice vaccinated with ChAdOx1 ZIKV candidates. Infection enhancement fold was calculated as the ratio of focus-forming units (FFU) of an anti-DENV2 monoclonal antibody to that of the FFU in the presence of serial dilutions of mouse sera collected 4 weeks after ChAdOx1 ZIKV vaccination. Each coloured line and shape represents a mouse for each group. n = 6/vaccinated group. Data represent three technical replicates, with a positive control anti-DENV2 antibody
